Clinical Trials Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. May 28, 2023; 29(20): 3133-3144
Published online May 28, 2023. doi: 10.3748/wjg.v29.i20.3133
Figure 1
Figure 1 Flow chart of the study. PPI: Proton pump inhibitor; ITT: Intention-to-treat analysis; PP: Per-protocol analysis; UBT: Urea breath test; H. pylori: Helicobacter pylori.
Figure 2
Figure 2 Eradication rates stratified by number of prior treatment failures. ITT: 93.6% vs 93.3% vs 83.3%, P = 0.433; PP: 93.2% vs 93.3% vs 83.3%, P = 0.585). ITT: Intention-to-treat analysis; PP: Per-protocol analysis.
Figure 3
Figure 3 Impact of bacterial antibiotic resistance on eradication rate. ITT: Clarithromycin resistant vs clarithromycin sensitive, P = 1.00; levofloxacin resistant vs levofloxacin sensitive, P = 1.00; PP: Clarithromycin resistant vs clarithromycin sensitive, P = 1.00; levofloxacin resistant vs levofloxacin sensitive, P = 1.00). R-CLA: Clarithromycin resistant; S-CLA: Clarithromycin sensitive; R-LEV: Levofloxacin resistant; S-LEV: Levofloxacin sensitive; ITT: Intention-to-treat analysis; PP: Per-protocol analysis.